Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against Aquestive Therapeutics for allegedly misleading investors about FDA approval prospects for its drug Anaphylm. The FDA identified deficiencies in Aquestive's New Drug Application, causing a 37% stock price drop. The firm is examining possible wrongdoing by company directors and officers. Shareholders may have legal options and are encouraged to contact the law firm for more information.

Aquestive Therapeutics saw a 37% stock drop amid an investigation into possible false statements about FDA approval prospects. For readers following the health sector, here is Pluang's market snapshot as of Oct 07, 2026 20:05 WIB: out of 100 priced US health stocks, 46 rose and 50 fell. Notable movers include Danaher Corporation (DHR) at USD 220.01 with a 1-day change of +2.06%, AbCellera Biologics Inc (ABCL) at USD 12.88 with -2.05%, and Novavax Inc (NVAX) at USD 11.09 with -2.03%.

Read Full Story: https://news.google.com/rss/articles/CBMirwFBVV95cUxQeWpZTksyVEFudlNTUHlCM3Br...